Human ASAH1 activation kit by CRISPRa

CAT#: GA100309

ASAH1 CRISPRa kit - CRISPR gene activation of human N-acylsphingosine amidohydrolase 1



  See Other Versions

CNY 12255.00


货期*
4周

规格
    • 1 kit

Product images

推荐一起购买 (3)
Rabbit Polyclonal ASAH1 Antibody
    • 100 ug

CNY 5808.00


ASAH1 (Myc-DDK-tagged)-Human N-acylsphingosine amidohydrolase (acid ceramidase) 1 (ASAH1), transcript variant 2
    • 10 ug

CNY 3656.00
CNY 3990.00


ASAH1 Rabbit polyclonal Antibody
    • 100 ul

CNY 1999.00
CNY 3280.00

Specifications

Product Data
Format 3 gRNAs (5ug each), 1 scramble ctrl (10ug) and 1 enhancer vector (10ug)
Symbol ASAH1
Locus ID 427
Kit Components

GA100309G1, ASAH1 gRNA vector 1 in pCas-Guide-GFP-CRISPRa

GA100309G2, ASAH1 gRNA vector 2 in pCas-Guide-GFP-CRISPRa

GA100309G3, ASAH1 gRNA vector 3 in pCas-Guide-GFP-CRISPRa

1 CRISPRa-Enhancer vector, SKU GE100056

1 CRISPRa scramble vector, SKU GE100077

Reference Data
RefSeq NM_001127505, NM_004315, NM_177924, NM_001363743
Synonyms AC; ACDase; ASAH; PHP; PHP32; SMAPME
Summary This gene encodes a member of the acid ceramidase family of proteins. Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed. Processing of this preproprotein generates alpha and beta subunits that heterodimerize to form the mature lysosomal enzyme, which catalyzes the degradation of ceramide into sphingosine and free fatty acid. This enzyme is overexpressed in multiple human cancers and may play a role in cancer progression. Mutations in this gene are associated with the lysosomal storage disorder, Farber lipogranulomatosis, and a neuromuscular disorder, spinal muscular atrophy with progressive myoclonic epilepsy. [provided by RefSeq, Oct 2015]
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Documents

Other Versions

Customer Reviews 
Loading...